newsfilter
← Latest News
PR Newswire·

SkinTE® Met Primary and Secondary Endpoints in Multicenter, Randomized Controlled Trial in Venous Leg Ulcers

SALT LAKE CITY, Feb. 22, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced results from a multi-center randomized controlled trial evaluating treatment of Venous Leg Ulcers (VLU) with its investigational product SkinTE® plus standard of